https://www.selleckchem.com/pr....oducts/brefeldin-a.h
) with male predominance (63% male) were selected. On follow-up, 123 (66%) had sCMR while recurrence was found in 34% (p 0.05). No significant difference in demographics was found between two groups. Median PFS time was 34 months (22.8 - 45.1 months). On ROC analysis, only baseline highest SUVmax was found as a significant independent predictor of disease recurrence at a cut off 22.6 (highest area under curve 0.595; SE 0.046; p 0.05). We conclude that recurrence is found in 34% of DLBCL patients with a negative interim 1
Like
Comment
Share
